Submission to the ANSM as part of a clinical trial requiring adaptation in connection with COVID-19:

Substantial Modification

• Submission to: ams-essaiscliniques@ansm.sante.fr

Attention: it is imperative to name the email mentioning:

• “MSA-COVID-19 / Type of trial / Trial Phase N° / EudraCT N° / Therapeutic area”
  or

•  “MSI-COVID-19 / Type of trial / Trial Phase N° / EudraCT N° / Therapeutic area

Urgent Security Measure

• Submission to: vig-essaiscliniques@ansm.sante.fr

Attention : it is imperative to name the mail with the following rule : COVID-19_MUS EudraCT_substance code